Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843975 | 0.89 | ALDH1A1 (0.59) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL1843232 | 0.85 | MAPT (0.68) | MAPTL3MBTL1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15687598 | 0.85 | POLB (0.61) | MAPTL3MBTL1CA1CA2KMT2A | |
| SCHEMBL30202595 | 0.85 | POLB (0.58) | MAPTL3MBTL1CA1CA2KMT2A | |
| SCHEMBL28515255 | 0.85 | POLB (0.58) | MAPTL3MBTL1CA1CA2KMT2A | |
| SCHEMBL7164868 | 0.84 | MAPT (0.84) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL2879386 | 0.84 | MAPT (0.60) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL5361493 | 0.83 | MAPT (0.70) | MAPTL3MBTL1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9687209 | 0.83 | MAPT (0.53) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL9688910 | 0.83 | HTR6 (0.53) | MAPTL3MBTL1CA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-5171748-A | For hypertension, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | MAPT 1614/4885L3MBTL1 4513/4885CA1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.